FDA Initiates Safety Review Of Weight Loss Medication Alli And Xenical
On August 24, 2009, the Food and Drug Administration ("FDA") issued an “Early Communication” to inform the public about concerns related to the weight loss medication, Orlistat, and potential injury to the liver.
The FDA announced there were 32 reports of liver injury suspected to be associated with the use of Orlistat between 1999 and 2008. The medication is available by prescription, and is marketed as Xenical (120 milligrams). The medication is also marketed and available over the counter under the brand name Alli (60 milligrams).
Potential side effects from Orlistat may manifest themselves as jaundice, abdominal pain, nausea, vomiting, brown urine, weakness, fatigue, fever, loss of appetite and itching. If you have experienced these symptoms and have ingested the weight loss medication, you should consult your health care professional and report the symptoms to the FDA’s MedWatch Adverse Event Reporting program.
If you have been injured as a result of using Orlistat either as Xenical and/or Alli, please contact us to discuss your legal options.